Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina T Saunders

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Biostatistics (Oxford, England)|November 1, 2017
A classical regression framework for mediation analysis: fitting one model to estimate mediation effectsChristina T Saunders, Jeffrey D Blume
Multivariate Behavioral Research|April 2, 2019
A Regression Framework for Causal Mediation Analysis with Applications to Behavioral ScienceChristina T Saunders, Jeffrey D Blume
JAMA Ophthalmology|August 19, 2021
Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of PrematurityRaymond T Kraker, David K Wallace, Roy W Beck, et al.
BMC Nephrology|February 6, 2021
Effect of balanced crystalloids versus saline on urinary biomarkers of acute kidney injury in critically ill adultsBlake E Funke, Karen E Jackson, Wesley H Self, et al.
Critical Care Medicine|January 27, 2018
Acute Kidney Injury and Subsequent Frailty Status in Survivors of Critical Illness: A Secondary AnalysisKhaled Abdel-Kader, Timothy D Girard, Nathan E Brummel, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Intensive Care Medicine|July 12, 2021
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M Arabi, Anthony C Gordon, Lennie P G Derde, et al.
JAMA|December 16, 2022
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial, Alisa M Higgins, Lindsay R Berry, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Biostatistics (Oxford, England)|November 1, 2017
A classical regression framework for mediation analysis: fitting one model to estimate mediation effectsChristina T Saunders, Jeffrey D Blume
Multivariate Behavioral Research|April 2, 2019
A Regression Framework for Causal Mediation Analysis with Applications to Behavioral ScienceChristina T Saunders, Jeffrey D Blume
JAMA Ophthalmology|August 19, 2021
Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of PrematurityRaymond T Kraker, David K Wallace, Roy W Beck, et al.
BMC Nephrology|February 6, 2021
Effect of balanced crystalloids versus saline on urinary biomarkers of acute kidney injury in critically ill adultsBlake E Funke, Karen E Jackson, Wesley H Self, et al.
Critical Care Medicine|January 27, 2018
Acute Kidney Injury and Subsequent Frailty Status in Survivors of Critical Illness: A Secondary AnalysisKhaled Abdel-Kader, Timothy D Girard, Nathan E Brummel, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Intensive Care Medicine|July 12, 2021
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M Arabi, Anthony C Gordon, Lennie P G Derde, et al.
JAMA|December 16, 2022
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial, Alisa M Higgins, Lindsay R Berry, et al.
Pageof 3